KNSA · Kiniksa Pharmaceuticals International, plc · Executive Compensation
$76.31
+0.52 (+0.69%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$11.72B
Shares
156.05M
Volume · Oct 5
391.51K
Avg daily vol (3M)
599.19K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Eben Tessari | Chief Strategy Officer | Resigned | 2026-05-01 |
| Eben Tessari | Chief Strategy Officer | Appointed | 2026-01-14 |
| Ross Moat | Chief Operating Officer and principal operating officer | Appointed | 2026-01-14 |
| M. Cantey Boyd | member of the Class III directors | Appointed | 2024-10-07 |